Form 8-K - Current report:
SEC Accession No. 0001493152-24-038718
Filing Date
2024-09-30
Accepted
2024-09-30 09:10:10
Documents
16
Period of Report
2024-09-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42367
2 ex99-1.htm EX-99.1 17357
3 ex99-1_001.jpg GRAPHIC 15202
  Complete submission text file 0001493152-24-038718.txt   312709

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cldi-20240930.xsd EX-101.SCH 3813
5 XBRL DEFINITION FILE cldi-20240930_def.xml EX-101.DEF 30090
6 XBRL LABEL FILE cldi-20240930_lab.xml EX-101.LAB 36817
7 XBRL PRESENTATION FILE cldi-20240930_pre.xml EX-101.PRE 27113
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5966
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 241336950
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)